Corvus Pharmaceuticals Inc (CRVS)

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

Hookipa Pharma (NASDAQ:HOOK) and Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Survey - Defense World

Defense World

Understanding the Risks of Investing in Corvus Pharmaceuticals Inc (CRVS) – Knox Daily - Knox Daily

Knox Daily

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Crosses Above 50-Day Moving Average of $1.77 - MarketBeat

MarketBeat

Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) market cap surged US$9.8m last week, individual investors who have a lot riding on the company were rewarded - Simply Wall St

Simply Wall St

Co-Founder Richard Miller Just Bought 8.5% More Shares In Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Yahoo News Australia

Yahoo News Australia

Corvus Pharmaceuticals director acquires $4.9m in company warrants - Investing.com

Investing.com

OrbiMed Advisors buys $4.9m in Corvus Pharmaceuticals warrants - Investing.com Nigeria

Investing.com Nigeria

Richard A. Md Miller Purchases 577634 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock - Defense World

Defense World

Corvus Pharmaceuticals (NASDAQ:CRVS) PT Raised to $8.00 at Oppenheimer - Defense World

Defense World

William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock - MarketBeat

MarketBeat

Corvus Pharmaceuticals executive buys $34,624 in company stock By Investing.com - Investing.com

Investing.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $8.00 - MarketBeat

MarketBeat

Corvus Pharmaceuticals CEO buys $1m in company shares - Investing.com

Investing.com

Earnings call: Corvus Pharmaceuticals Q1 2024 financial results and trials update - Investing.com

Investing.com

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

A significant driver of top-line growth: Corvus Pharmaceuticals Inc (CRVS) – Sete News - SETE News

SETE News

William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock - MarketBeat

MarketBeat

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Corvus Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha

Seeking Alpha

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results - 06.05.2024 - wallstreet:online

wallstreet:online

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | Daily - Daily Guardian Canada

Daily Guardian Canada

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Corvus Pharmaceuticals Inc (NASDAQ:CRVS): It's all about numbers this morning – US Post News - US Post News

US Post News

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results - Yahoo Finance

Yahoo Finance

What Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry? - Yahoo Movies Canada

Yahoo Movies Canada

What Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry? - Yahoo Movies Canada

Yahoo Movies Canada

Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Monday - Defense World

Defense World

Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Monday - Defense World

Defense World

Corvus Pharmaceuticals (CRVS) to Release Earnings on Monday - MarketBeat

MarketBeat

Corvus Pharmaceuticals (CRVS) to Release Earnings on Monday - MarketBeat

MarketBeat

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 - WICZ

WICZ

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

GlobeNewswire Inc.

Corvus Pharmaceuticals raises $30.6 million in stock sale By Investing.com - Investing.com UK

Investing.com UK

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

GlobeNewswire Inc.

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 - Investing.com India

Investing.com India

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update - Defense World

Defense World

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

Zacks Investment Research

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

GlobeNewswire Inc.

CRVS Stock Quote Price and Forecast - CNN

CNN

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Zacks Investment Research

Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns - TipRanks.com - TipRanks

TipRanks

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Corvus: Q4 Earnings Snapshot - Quartz

Quartz

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

GlobeNewswire Inc.

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully - Yahoo Finance

Yahoo Finance

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely? - Simply Wall St

Simply Wall St

Soquelitinib Receives FDA Orphan Drug Designation FDA for T-Cell Lymphoma - www.oncnursingnews.com/

www.oncnursingnews.com/

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

Zacks Investment Research

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

GlobeNewswire Inc.